Perflutren Lipid Microspheres

Phase 3Small molecule

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Perflutren Lipid Microspheres is one of 117 small molecule programs targeting Portal Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Portal HypertensionPreclinical

Active, not recruiting

Liver CancerPreclinical

Active, not recruiting

Breast CancerPhase 2/Phase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Adenocard

Astellas

Preclinical

1 7

Voltaren

Novartis

Preclinical

1 8

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 9

Tricor

JJagotec

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Portal Hypertension

NCT06797193

Q4 2027

Phase 1Recruiting

Ultrasound

NCT06171607

Clinical

Trials by Indication[1]

Liver Cancer3 trials

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03045497·15 enrolled

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn·UUniversity of Southern California·N/A·NCT03300401

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

Completed·SStanford University·N/A·NCT02424955·11 enrolled

Ultrasound3 trials

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

Recruiting·UUniversity of Southern California·Phase 1·NCT06171607·100 enrolled

Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound

Unknown status·UUniversity of Virginia·N/A·NCT00631553·20 enrolled

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03297112·12 enrolled

Breast Cancer1 trial

Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer

Recruiting·KKibo Nam·Phase 2/3·NCT04715958·200 enrolled

Radiofrequency Ablation1 trial

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

Completed·UUniversity of California, Davis·N/A·NCT00584402·8 enrolled

Prostate Cancer1 trial

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Active, not recruiting·TThomas Jefferson University·Phase 3·NCT05336786·70 enrolled

1 more indication

Portal Hypertension1 trial

Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Recruiting·MMayo Clinic·N/A·NCT06797193·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Perflutren Lipid Microspheres. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren Lipid Microspheres compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perflutren Lipid Microspheres. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Perflutren Lipid Microspheres

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Liver Cancer3 trials

Ultrasound3 trials

Breast Cancer1 trial

Radiofrequency Ablation1 trial

Prostate Cancer1 trial

Portal Hypertension1 trial

References

Drug Info

Quick Facts

Related News